A systematic review of economic evaluations of treatment regimens in multiple myeloma

References

• Röllig C, Knop S, Bornhäuser M. Multiple myeloma. Lancet. 2015;385:2197–2208.
   PubMed Web of Science ®Google Scholar
• Cancer Stat Facts: Myeloma. National cancer institute surveillance, epidemiology, and end results program web site. [ cited 2019 Jan 19]. Avilable from: https://seer.cancer.gov/statfacts/html/mulmy.html
   Google Scholar
• Cowan AJ, Allen C, Barac A, et al. Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221–1227. DOI:10.1001/jamaoncol.2018.2128
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520.
   PubMed Web of Science ®Google Scholar
• Abramson HN. The multiple myeloma drug pipeline-2018: a review of small molecules and their therapeutic targets. Clin Lymphoma Myeloma Leuk. 2018;18(9):611‐27.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma. Version 2.2019. [ cited 2019 Jan 19]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
   Google Scholar
• Jain T, Sonbol MB, Firwana B, et al. High-dose chemotherapy with early autologous stem cell transplantation compared to standard dose chemotherapy or delayed transplantation in patients with newly diagnosed multiple myeloma: A systematic review and meta-analysis. Biol Blood Marrow Transplant. 2019;25(2):239–247.
   PubMed Web of Science ®Google Scholar
• Dhakal B, Szabo A, Chhabra S, et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: A systematic review and meta-analysis. JAMA Oncol. 2018;4(3):343–350.
   PubMed Web of Science ®Google Scholar
• Roy A, Kish JK, Bloudek L, et al. Estimating the costs of therapy in patients with relapsed and/or refractory multiple myeloma: a model framework. Am Health Drug Benefits. 2015;8(4):204–215.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Evans DB, Acharya A, et al. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9(3):235–251.
   PubMed Web of Science ®Google Scholar
• Harris A, Buxton M, O’Brien B, et al. Using economic evidence in reimbursement decisions for health technologies: experience of 4 countries. Expert Rev Pharmacoecon Outcomes Res. 2001;1:7–12.
   PubMedGoogle Scholar
• Sarin R. Criteria for deciding cost-effectiveness for expensive new anti-cancer agents. J Cancer Res Ther. 2008;4:1–2.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Schulpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
   Google Scholar
• Carlson JJ, Guzauskas GF, Chapman RH, et al. Cost-effectiveness of drugs to treat relapsed/refractory multiple myeloma in the United States. J Manag Care Spec Pharm. 2018 Jan;24(1):29–38.
   PubMed Web of Science ®Google Scholar
• Zhang TT, Wang S, Wan N, et al. Cost-effectiveness of Daratumumab-based triplet therapies in patients with relapsed or refractory multiple myeloma. Clin Ther. 2018;40(7):1122–1139.
   PubMed Web of Science ®Google Scholar
• Pelligra CG, Parikh K, Guo S, et al. Cost-effectiveness of pomalidomide, carfilzomib, and daratumumab for the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma in the United States. Clin Ther. 2017;39(10):1986–2005.e5.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Houisse I, Májer I, et al. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States. Expert Rev Hematol. 2017;10(12):1107–1119.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Cavenagh JD, Belch AR, et al. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma. J Med Econ. 2016;19(3):243–258.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Campioni M, Á B, et al. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. J Med Econ. 2016;19(11):1061–1074.
   PubMed Web of Science ®Google Scholar
• Shah GL, Winn AN, Lin PJ, et al. Cost-effectiveness of autologous hematopoietic stem cell transplantation for elderly patients with multiple myeloma using the surveillance, epidemiology, and end results-medicare database. Biol Blood Marrow Transplant. 2015;21(10):1823–1829.
   PubMed Web of Science ®Google Scholar
• Garrison LP Jr, Wang ST, Huang H, et al. The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. Oncologist. 2013;18(1):27–36.
   PubMed Web of Science ®Google Scholar
• Qerimi V, Nestorovska AK, Sterjev Z, et al. Cost-effectiveness analysis of treating transplant-eligible multiple myeloma patients in Macedonia. Clinicoecon Outcomes Res. 2018;10:327–338.
   PubMed Web of Science ®Google Scholar
• Borg S, Nahi H, Hansson M, et al. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden. Acta Oncol. 2016;55(5):554–560.
   PubMed Web of Science ®Google Scholar
• Brown RE, Stern S, Dhanasiri S, et al. Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales. Eur J Health Econ. 2013;14(3):507–514.
   PubMed Web of Science ®Google Scholar
• Corso A, Mangiacavalli S, Cocito F, et al. Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis. PLoS One. 2013;8(9):e75047.
   PubMed Web of Science ®Google Scholar
• Fragoulakis V, Kastritis E, Psaltopoulou T, et al. Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece. Cancer Manag Res. 2013;5:37–48.
   PubMedGoogle Scholar
• Möller J, Nicklasson L, Murthy A. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib. J Med Econ. 2011;14(6):690–697.
   PubMedGoogle Scholar
• Hornberger J, Rickert J, Dhawan R, et al. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: swedish perspective. Eur J Haematol. 2010;85(6):484–491.
   PubMed Web of Science ®Google Scholar
• Prinja S, Kaur G, Malhotra P, et al. Cost-effectiveness of autologous stem cell treatment as compared to conventional chemotherapy for treatment of multiple myeloma in India. Indian J Hematol Blood Transfus. 2017;33(1):31–40.
   PubMed Web of Science ®Google Scholar
• Aceituno S, Gozalbo I, Appierto M, et al. Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile. Medwave. 2018;18(3):e7220.
   PubMed Web of Science ®Google Scholar
• Byford S, Raftery J. Perspectives in economic evaluation. BMJ. 1998;316(7143):1529–1530.
   PubMed Web of Science ®Google Scholar
• Economic modelling [online]. York: York health economics consortium; 2016. Available from: https://www.yhec.co.uk/glossary/economic-modelling/
   Google Scholar
• Williams C, Lewsey JD, Mackay DF, et al. Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and markov decision-analytic modeling. Med Decis Making. 2017;37(4):427–439.
   PubMed Web of Science ®Google Scholar
• Gaultney JG, Redekop WK, Sonneveld P, et al. Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology. Eur J Cancer. 2011;47(10):1458–1467.
   PubMed Web of Science ®Google Scholar
• Chalfin DB. Evidence-based medicine and cost-effectiveness analysis. Crit Care Clin. 1998;14(3):525–537.
   PubMed Web of Science ®Google Scholar
• Aguiar PM, Lima TM, Storpirtis S. Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality? J Clin Pharm Ther. 2016;41(2):189–197.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 2013;11:159.
   PubMed Web of Science ®Google Scholar
• Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations. pharmacoeconomics. 2018;36(7):745–758.
   PubMed Web of Science ®Google Scholar
• Garattini L, Koleva D, Casadei G. Modeling in pharmacoeconomic studies: funding sources and outcomes. Int J Technol Assess Health Care. 2010;26(3):330–333.
   PubMed Web of Science ®Google Scholar